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Abstract: Thymidylate synthase (TYMS) enzyme is an anti-cancer target given its role in DNA
biosynthesis. TYMS inhibitors (e.g., 5-Fluorouracil) can lead to drug resistance through an
autoregulatory mechanism of TYMS that causes its overexpression. Since G-quadruplexes (G4)
can modulate gene expression, we searched for putative G4 forming sequences (G4FS) in the TYMS
gene that could be targeted using polypurine reverse Hoogsteen hairpins (PPRH). G4 structures
in the TYMS gene were detected using the quadruplex forming G-rich sequences mapper and
confirmed through spectroscopic approaches such as circular dichroism and NMR using synthetic
oligonucleotides. Interactions between G4FS and TYMS protein or G4FS and a PPRH targeting
this sequence (HpTYMS-G4-T) were studied by EMSA and thioflavin T staining. We identified a
G4FS in the 5’UTR of the TYMS gene in both DNA and RNA capable of interacting with TYMS
protein. The PPRH binds to its corresponding target dsDNA, promoting G4 formation. In cancer
cells, HpTYMG-G4-T decreased TYMS mRNA and protein levels, leading to cell death, and showed a
synergic effect when combined with 5-fluorouracil. These results reveal the presence of a G4 motif in
the TYMS gene, probably involved in the autoregulation of TYMS expression, and the therapeutic
potential of a PPRH targeted to the G4FS.
Keywords: G-quadruplex; PPRH; thymidylate synthase; anti-tumor therapy; 5-fluorouracil; gene silencing;
gene regulation
1. Introduction
Thymidylate synthase (TYMS) has been widely studied as an anti-cancer target due to its essential
role in the de novo synthesis of 2’-deoxythymidine-5’-monophosphate (dTMP), a critical precursor for
DNA biosynthesis. TYMS catalyzes the conversion of 2’-deoxyuridine 5’-monophosphate (dUMP) to
dTMP by transferring the methyl group from the 5,10-methylenetetrahydrofolate molecule (mTHF).
Then, dTMP is successively phosphorylated to form 2’-deoxythymidine-5’-triphosphate (dTTP),
generating one of the four fundamental nucleoside triphosphates involved in DNA synthesis [1,2].
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TYMS inhibition affects highly proliferative cells (e.g., cancer cells) and has been established
as a classic chemotherapeutic treatment during the last few decades [3]. Since its development
in 1957, the nucleobase 5-fluorouracil (5-FU) has become one of the most widely used TYMS
inhibitors for the treatment of different types of cancer, either as a single agent or in combination
with other chemotherapeutics [2,4]. Intracellularly, 5-FU is converted to 5-fluoro-2’-deoxyuridine-
5’-monophosphate (FdUMP), which is an analog of the endogenous ligand dUMP and binds to the
nucleotide-binding domain of TYMS. This FdUMP-TYMS-mTHF ternary complex inhibits TYMS
activity and leads to the suppression of dTMP synthesis, thus producing deoxynucleotide pool
imbalance, increased levels of deoxyuridine triphosphate (dUTP) and, ultimately, DNA damage [4,5].
Nevertheless, the effectiveness of fluoropyrimidines or other TYMS inhibitors is compromised by the
development of drug resistance. Some of these have been associated with high TYMS protein levels
and are thought to be related to an autoregulatory mechanism of TYMS protein that modulates its own
expression [6,7].
It has been proposed that the ligand-free TYMS protein is capable of binding to its own mRNA
and represses its own translation. Two mRNA binding sites for TYMS have been identified so far in
its mRNA: one located in the 5’ untranslated region (5’UTR), containing the translational start site
(binding site I), and the other in the mRNA-coding region (binding site II) [8,9]. When TYMS protein is
bound to dUMP or TYMS inhibitors such as fluoropyrimidines or antifolates [10], it cannot bind to its
own mRNA and TYMS mRNA translation is not inhibited. This mechanism of translational regulation
would explain the increased TYMS protein levels observed in tumor resistance cells [8,10,11].
Different strategies to overcome drug resistance have been developed, including antisense
oligodeoxynucleotides (ASO) targeting different TYMS mRNA regions such as the protein binding site
I, which might be an important regulator of translation [10]. The goal in the present work was to target
other regulatory elements located in the TYMS gene, such as G-quadruplex structures (G4s). In the last
few decades, the interest in G4s as gene regulation elements for anti-tumor applications has increased
considerably [12]. G4s are nucleic acid secondary structures formed by guanine-rich RNA or DNA
sequences whose basic structural unit is called G-tetrad, a square-planar arrangement of four guanines
held together through Hoogsteen type associations. [13,14]. Stacking a minimum of two of these
G-tetrads produces the four-stranded G4 structure that is further stabilized by monovalent cations
(especially K+) and presents a high thermodynamic stability under physiological conditions [15].
G4s may have an important role in controlling different biological processes such as DNA replication [16],
telomere maintenance [17] and mRNA transcription, processing and translation [18,19]. For this reason,
G4s are mainly found in regulatory regions such as promoters, 5’UTRs, splicing sites and telomeres [20].
Here, we targeted a G4 forming sequence (G4FS) in the 5’UTR of the TYMS gene using a gene
silencing tool developed in our laboratory named polypurine reverse Hoogsteen (PPRH) hairpins [21].
These molecules are non-modified single-stranded oligodeoxynucleotides formed by two antiparallel
polypurine mirror repeat domains linked by a five-thymidine loop (5T). The intramolecular linkage
consists of reverse Hoogsteen bonds between the purines, forming the hairpin structure. PPRHs can
bind in a sequence-specific manner to polypyrimidine targets in the double-stranded DNA (dsDNA)
via Watson–Crick bonds, thus producing a triplex structure and displacing the fourth strand of the
dsDNA. This local distortion of the dsDNA leads to a transcriptional disruption that provokes the
knockdown of the targeted gene [22]. Therefore, it is essential for PPRH design to find polypyrimidine
tracts within the target gene sequence, which are mainly present in promoter or intronic regions [23].
During the last decade, we have used PPRHs as gene silencing tools for anti-cancer therapy [22,24–27],
immunotherapy approaches [28–30] and targeting genes involved in resistance to chemotherapeutic
drugs like methotrexate [31].
In this work, we identified and validated a G4 structure in the TYMS gene that can be targeted by a
PPRH as a new approach to down-regulate TYMS expression. Treatment with this DNA hairpin was very
effective against human cancer cells, and it acted synergistically when administered together with 5-FU.
Additionally, we aimed to study the role of this G4 structure in the modulation of TYMS expression.
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2. Results
2.1. Detection of a G4 Structure in the 5’UTR of TYMS
We searched G4FSs that could modulate TYMS expression using the quadruplex forming G-rich
sequences (QGRS) mapper (Figure 1A). The sequence with the highest score (G20) was found in
the 5’UTR of this gene (Figure 1B), according to reference [32] and in agreement with the human
TYMS mRNA sequence NM_001071.3. However, in the last sequence version available in the NCBI
gene database (NM_001071.4), the 5’UTR has been shortened (−69 nt) and the G4FS is excluded
from the 5’UTR. Therefore, we carried out PCR reactions from either genomic or reverse transcribed
DNA in order to test whether this G4FS was positioned in this untranslated region. Both genomic
DNA (gDNA) and cDNA samples originated a main product of 184 bp (Figure 1C), thus confirming
that the identified G4FS was actually located within the 5’UTR of the TYMS gene and not in the
promoter. Moreover, we confirmed by sequencing that the 184 bp PCR product amplified from the
cDNA sample corresponded to the 5’UTR sequence containing the G4FS. The human TYMS mRNA
sequence (NM_001071.3) was subjected to the Triplex-Forming Oligonucleotide (TFO) searching
tool [33]. The output (Figure 1D) was confronted with the list obtained with the QGRS mapper
(Figure 1A). The matching sequence was used to design the PPRH targeting the G4FS (HpTYMS-G4-T)
to decrease TYMS expression (Figure 1E). The mechanism of action of HpTYMS-G4-T is depicted
in Figure 1F.
2.2. G4 Structure Confirmation in Both RNA and DNA
Next, we proceeded to confirm whether the G4FS (ssDNA-G4-Fw and RNA-G4) could form a G4
structure using different spectroscopic approaches such as circular dichroism (CD), UV absorbance
spectroscopy (UV) and fluorescence and nuclear magnetic resonance (NMR) using synthetic
oligonucleotides. UV absorbance and CD spectroscopies have played important roles in the verification
of G-quadruplex folding [34,35]. Denaturation or melting curves recorded at 295 nm are commonly
used to determine the thermodynamic properties of G-quadruplex [34]. In addition, a thermal
difference spectrum (TDS) (absorption difference between unfolded and folded form) is applied in
order to confirm the existence of G-quadruplex structures and differentiate them from other DNA
structures such as duplexes or triplexes [36].
Oligonucleotides ssDNA-G4-Fw and RNA-G4 (Table 1) contain the G4FS identified by the QGRS
mapper (Figure 1A,B) in both DNA and RNA backbones. The melting curves of these oligonucleotides
were recorded in two different buffers. One of them, K+ solution, contains a relatively large amount
of potassium, which has been described to stabilize the G-quadruplex structure. The other is a
phosphate-buffered solution (PBS) containing sodium cations. The thermal denaturation profiles
exhibited hypochromism at 295 nm with increasing temperature, indicating the denaturation of a
potential G-quadruplex structure. Both denaturation curves showed similar melting profiles with
similar melting temperatures, being 37 ◦C in K+ solution, which is slightly higher than in PBS (35 ◦C) for
ssDNA-G4-Fw. RNA-G4 showed similar behavior, with increased stability compared to ssDNA-G4-Fw,
47 ◦C in K+ buffer and 40 ◦C in PBS. TDS, especially in K+ buffer, showed the spectra profile assigned
to a G-quadruplex with maxima around 243 and 273 and minima at around 295 nm [36] (Figure S1).
CD spectra were recorded using the same buffers (Figure 2A,B). Spectra were indicative of hybrid
G-quadruplex, with positive bands at ~260 and 295 nm and a negative band at 245 nm for ssDNA-G4-Fw
(Figure 2A), and a parallel G-quadruplex structure with positive bands ~260 and a negative band at
245 nm for RNA-G4 (Figure 2B). A schematic illustration of the possible G-quadruplex structure of
RNA-G4 is shown in Figure 2C.
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Putative G4-forming sequences detected in the TYMS gene using the QGRS mapper. The positions of 
the identified G4FS are referred to as the transcription start site considering the TYMS mRNA 
sequence NM_001071.3. The blue underlined Guanines (Gs) represent the ones implicated in G4 
formation. (B) Localization of the G4FS with the higher G-score in the TYMS gene sequence 
(NM_001071.3). The orange highlighted sequence corresponds to G4FS. (C) The G4FS is located in the 
5’UTR of the TYMS gene. PCR products (184 bp) obtained after amplification with primers 5’UTR-
TYMS-Fw and 5’UTR-TYMS-Rv of both gDNA and cDNA/RNA samples. PCR products were 
Figure 1. Identification of a G4FS in the TYMS gene and design of a PPRH targeting this site. (A) Putative
G4-forming sequences detected in the TYMS gene using the QGRS mapper. The positions of the
identified G4FS are referred to as the transcription start site considering the TYMS mRNA sequence
NM_001071.3. The blue underlined Guanines (Gs) represent the ones implicated in G4 formation.
(B) Localization of the G4FS with th higher G-score in the TYMS gene sequ nce (NM_001071.3).
The orange highlighted sequence corresponds to G4FS. (C) The G4FS i located in the 5’UT of the
TYMS gene. PCR products (184 bp) obtained after amplification with primers 5’UTR-TYMS-Fw and
5’UTR-TYMS-Rv of both gDNA and cDNA/RNA samples. PCR products were resolved in a 6%
polyacrylamide gel electrophoresis. (D) The first two polypurine sequences found in TYMS mRNA
using the TFO searching tool. (E) Sequence of the specific PPRH targeting the G4FS (HpTYMS-G4-T),
its corresponding Watson–Crick negative control (HpTYMS-G4-T-WC) and a scramble negative
control (HpSC4). (F) Scheme showing the potential strand displacement produced when the PPRH
(HpTYMS-G4-T) is mixed with dsDNA-G4FS. The formation of the antiparallel triplex by binding of
the PPRH to the polypyrimidine oligonucleotide dissociates the polypurine oligonucleotide.
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Table 1. Oligonucleotides used in this study.
Name Sequence (5’-3’) Length Assay
5’UTR-TYMS-Fw GAGCAGGAAGAGGCGGAGCG 20 PCR
5’UTR-TYMS-Rv GCAGCTCCGAGCCGGCCACAGG 22 PCR
APRT-Ex1-Fw CACCCCAGGCGTGGTATTCA 20 PCR
APRT-Ex2-Rv CTGCGATGTAGTCGATGCGG 20 PCR
TYMS-Fw CCTCGGTGTGCCTTTCAACATC 22 qPCR
TYMS-Rv GGTCTGGGTTCTCGCTGAAGC 21 qPCR
PPIB-Fw GGAGATGGCACAGGAGGAAA 20 qPCR
PPIB-Rv CGTAGTGCTTCAGTTTGAAGTTCTCA 26 qPCR
RNA-G4 GGGAAAAGGCGCGCGGAAGGGG 22 EMSA, CD, UV, Flu
ssDNA-G4-Fw-E GGGAAAAGGCGCGCGGAAGGGG 22 EMSA
ssDNA-G4-Rv-E CCCCTTCCGCGCGCCTTTTCCC 22 EMSA
ssDNA-G4-Fw CGGGAAAAGGCGCGCGGAAGGGGT 24 TGS, CD, UV, Flu, NMR
ssDNA-G4-Rv ACCCCTTCCGCGCGCCTTTTCCCG 24 TGS
PCR (polymerase chain reaction), qPCR (quantitative PCR), EMSA (electrophoretic mobility shift assay), CD (circular
dichroism), UV (UV absorbance spectroscopy), Flu (thioflavin T fluorescence spectroscopy), Thioflavin T gel staining
(TGS), NMR (nuclear magnetic resonance).
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Figure 2. Structural characterization of G4FS in both RNA and DNA oligonucleotides. CD spectra of
ssDNA-G4-Fw (A) and RNA-G4 (B) in K+ buffer (blue line) and PBS (red line) at 20 ◦C, showing a shape
consistent with the formation of G-quadruplex structures. (C) Illustration representing the G-quadruplex
folding of the G4-RNA sequence. Each color dot represents a ribonucleotide: adenine (rA), citosine (rC)
and guanine (rG). (D) Imino region of monodimensional 1H-NMR spectra of ssDNA-G4-Fw in H2O/D2O
(90:10) at different temperatures. The spectra show signals between 10 and 12 ppm, characteristic of
imino protons taking part in G-tetrads. Buffer conditions: 25 mM KPi pH 7, 100 mM KCl.
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The imino region of the one-dimensional 1H-NMR spectrum (Figure 2D) of ssDNA-G4-Fw showed
signals between 10 and 12 ppm, which are within the range of the chemical shifts of guanine imino
protons involved in G-tetrads. The signals observed between 12 and 13 ppm belong to imino protons
forming GC Watson–Crick base pairs. Most probably, these signals are due to the formation of G:C:G:C
tetrads within the G-quadruplex. Such tetrads, resulting from the association of two G:C base pairs,
are not unusual and accommodate well between G:G:G:G tetrads [37]. All the imino signals remained
visible at 45 ◦C (Figure 2D), indicating the remarkable thermal stability of the structure, which is
frequent for G-quadruplexes [15].
Thioflavin T (ThT) is an efficient fluorescent sensor of G-quadruplex and it has been used
to discriminate G-quadruplex structures from other structures [38]. To this end, we carried out
fluorescence spectra titrations by adding the oligonucleotide (ODN) dissolved in PBS to a solution of ThT.
We observed an increase in fluorescence with increasing concentrations of the ODN, which enables us to
determine an association constant following the method described in the literature [39]. The association
constants for ssDNA-G4-Fw were found to be 2.72 × 106 and 2.90 × 106 for RNA-G4, both in the range
of the values described for other G-quadruplexes [38] (Figure S2).
2.3. TYMS Protein Binds to the G4FS
To study the possible binding of the TYMS protein to the G4FS contained in the 5’UTR of the
TYMS gene, we performed different electrophoretic mobility shift assays (EMSA) using radioactively
labeled ssDNA-G4-Fw-E or RNA-G4 oligonucleotides (Table 1).
In the case of ssDNA-G4-Fw-E, we observed three shifted bands—two with high molecular
weight—when incubating the probe with purified TYMS protein (Figure 3A, lane 2). In a similar way,
incubation of a nuclear extract from cervical carcinoma cells (HeLa) with the probe produced the same
shifted bands (Figure 3A, lane 3–4) that could correspond to the binding of the TYMS protein present
in the nuclear extract. In contrast, the incubation of the ssDNA-G4-Fw-E probe with either bovine
serum albumin (BSA) or dihydrofolate reductase (DHFR) proteins as negative controls did not show
any shifted bands (Figure 3A, lane 5–6). Therefore, TYMS protein specifically binds to the G4FS located
in the 5’UTR of the TYMS gene.
Since we observed the binding of the TYMS protein to the ssDNA-G4-Fw-E probe, we checked
whether this binding could occur using the RNA sequence corresponding to the same G4FS.
The incubation of TYMS protein with the RNA probe (RNA-G4) showed three shifted bands
(Figure 3B, lane 2), thus demonstrating that TYMS protein binds to this particular G4FS located
in the 5’UTR of its own mRNA. The incubation of the probe with the BSA protein did not produce any
binding (Figure 3B, lane 3).
2.4. TYMS Protein and HpTYMS-G4-T Compete to Bind to the G4FS in the dsDNA
Since TYMS protein can also be found in the cell nucleus, we explored the possible binding of this
protein to the dsDNA corresponding to the G4FS. In these experiments, we observed a unique shifted
band when incubating the dsDNA-G4-E probe (prepared by hybridization of ssDNA-G4-Fw-E and
ssDNA-G4-Rv-E, Table 1) with TYMS protein (Figure 4A, lane 2). The intensity of this shifted band
was increased when a higher amount of TYMS protein was added to the reaction (Figure 4A, lane 3).
Additionally, the incubation of the probe with a HeLa nuclear extract (2 µg) produced a shifted
band with the same mobility as the one obtained with purified TYMS protein (Figure 4A, lane 4).
We confirmed that the binding of TYMS protein to the G4FS was specific since incubation with BSA or
DHFR proteins did not produce any shifted bands (Figure 4A, lane 5–6).
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RNA (B) probes corresponding to the G4FS. (A) Lane 1, ssDNA-G4-Fw-E probe alone; lane 2, ssDNA-
G4-Fw-E plus TYMS protein (1,5 µg); lane 3 and 4, ssDNA-G4-Fw-E plus nuclear protein extract (2 
µg) in duplicate; lane 5, ssDNA-G4-Fw-E plus BSA protein (2 µg); lane 6, ssDNA-G4-Fw-E plus DHFR 
protein (2 µg). (B) Lane 1, RNA-G4 probe alone; lane 2, RNA-G4 plus TYMS protein (1,5 µg); lane 3, 
Figure 3. Binding of TYMS protein to the G4FS mRNA. EMSAs using 32P-radiolabeled ssDNA (A)
or RNA (B) probes corresponding to the G4FS. (A) Lane 1, ssDNA-G4-Fw-E probe alone; lane 2,
ssDNA-G4-Fw-E plus TYMS protein (1.5 µg); lane 3 and 4, ssDNA-G4-Fw-E plus nuclear protein extract
(2 µg) in duplicate; lane 5, ssDNA-G4-Fw-E plus BSA protein (2 µg); lane 6, ssDNA-G4-Fw-E plus
DHFR protein (2 µg). (B) Lane 1, RNA-G4 probe alone; lane 2, RNA-G4 plus TYMS protein (1.5 µg);
lane 3, RNA-G4 plus BSA protein (2 µg). Arrows indicate the shifted bands corresponding to the
different molecular species.
Next, we designed the PPRH sequence (HpTYMS-G4-T) against the homopyrimidine
complementary sequence of G4FS (Figure 1E). Then, we demonstrated that this PPRH oligonucleotide
was able to bind the dsDNA-G4-E probe, observing one shifted band whose intensity increased
depending on the amount of HpTYMS-G4-T added to the reaction (10, 30 or 60 ng) (Figure 4B, lane 2–4).
We also performed a competition assay between HpTYMS-G4-T and TYMS protein. To do so, different
amounts of HpTYMS-G4-T (10, 30 and 60 ng) were added to the binding reaction, together with a fixed
amount of TYMS protein, showing a decrease in the intensity of the shifted band, corresponding to the
binding of TYMS protein to the probe (Figure 4B, lane 5–8). Interestingly, the shifted band corresponding
to the binding of HpTYMS-G4-T to the probe reappeared, and its intensity was proportional to the
amount of HpTYMS-G4-T added to the reaction (Figure 4B, lane 5–8). Therefore, we demonstrated
that HpTYMS-G4-T and TYMS protein bind to the same G4FS site in the dsDNA.
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(A) Lane 1, dsDNA-G4-E probe alone; lane 2, dsDNA-G4-E plus TYMS protein (1.5 µg); lane 3,
dsDNA-G4 plus T S r tei (3 µg); lane 4, dsDNA-G4-E plus HeLa nuclear protein extract (NE)
(2 µg); lane 5, dsDNA-G4-E plus BSA protein (2 µg); lane 6, dsDNA-G4-E plus DHFR protein (2 µg).
(B) Competition assay between the TYMS protein and the HpTYMS-G4-T for the binding to the G4FS
in the dsDNA. Lane 1, dsDNA-G4-E probe alone; lane 2, dsDNA-G4-E plus HpTYMS-G4-T (10 ng);
lane 3, dsDNA-G4-E plus HpTYMS-G4-T (30 ng); lane 4, dsDNA-G4-E plus HpTYMS-G4-T (60 ng);
lane 5, dsDNA-G4-E plus TYMS protein (1.5 µg); lane 6, dsDNA-G4-E plus TYMS protein (1.5 µg)
competed with HpTYMS-G4-T (10 ng); lane 7, dsDNA-G4-E plus TYMS protein (1.5 µg) competed with
HpTYMS-G4-T (30 ng); lane 8, dsDNA-G4-E plus TYMS protein (1.5 µg) competed with HpTYMS-G4-T
(60 ng). Arrows indicate the shifted bands corresponding to the different molecular species.
2.5. HpTYMS-G4-T Promotes the Formation of the G4 Structure
HpTYMS-G4-T was designed to bind to its polypyrimidine target sequence in the dsDNA and
form a DNA triplex. This would displace the G-rich sequence of the duplex that consequently could
fold into a G4 structure (Figure 1F). To verify this possibility, the products of different binding assays
were separated on a nondenaturing gel (Figure 5), which was then stained with ThT to detect the
G4 structures formed [40]. The ssDNA-G4-Fw sequence was stained by ThT, as expected for a G4
structure (Figure 5A, lane 1), while dsDNA-G4 (hybrid from ssDNA-G4-Fw and ssDNA-G4-Rv) did
not (Figure 5A, lane 2). The PPRH HpTYMS-G4-T was also detected by ThT staining, which is
consistent with the fact that its sequence contains two repeats of G4-Fw and thus is able to fold into G4
structures. The PPRH samples showed a strong band and a shadow since they can adopt different
conformations [24,41] (Figure 5A, lane 3). Incubation of dsDNA-G4 concurrently with the PPRH led to
the formation of two extra bands, the upper corresponding to the ssDNA-G4-Rv/PPRH DNA triplex
and the lower corresponding to the ssDNA-G4-Fw strand displaced from dsDNA-G4, which did
form a G4 structure (Figure 5A, lane 4). As a negative control, we incubated ssDNA-G4-Rv, which is
not a G4FS and, consequently, was not stained with ThT (Figure 5A, Lane 5). In addition, we used
HpTYMS-G4-T-WC, a hairpin intramolecularly bound by Watson–Crick base pairs and thus not able
to produce the DNA triplex and to displace the fourth strand. Accordingly, we did not observe the
formation of the triplex between HpTYMS-G4-T-WC and the dsDNA-G4 (Figure 5A, lane 7). However,
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since one of the domains of HpTYMS-G4-T-WC still contains a G4FS, the oligonucleotide was also
stained by ThT (Figure 6A, lane 6). Then, after staining the same gel with ethidium bromide (EthBr),
the species corresponding to dsDNA-G4 (Figure 5B, lane 2, lane 4 and lane 7) and ssDNA-G4-Rv
(Figure 5B, lane 5) were visualized. G4 structures were also detected when ThT was directly added to
the different binding assays incubations instead of electrophoresing the samples and staining the gel
afterwards (Figure 5C).
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Figure 5. DNA binding assays and G4 structure detection using ThT. Samples incubated at 90 ◦C
were cooled down slowly to room temperatur and loaded in a nondenaturing 12% acrylamide gel
supplem nted ith 10 mM KCl. The gel was visualiz u der UV light after ThT staining (A) and
EthBr staining. (B) Lane , ssDNA-G4-Fw alone; lane 2, sDNA-G4 alone; lane 3, HpTYMS-G4-T alone;
lane 4, dsDNA-G4-2 plus HpTYMS-G4-T; lane 5, ssDNA-G4-Rv alone; lane 6, HpTYMS-G4-T-WC
alone; lane 7, dsDNA-G4 plus HpTYMS-G4-T-WC. (C) G4 detection in samples directly incubated with
ThT and visualized under UV light. Samples were prepared as indicated in Section 4.11 of Materials
and Methods but containing 1 µM of each oligonucleotide. When samples reached room temperature,
8 µM of ThT was added and samples were visualized under UV light lamp or visible light.
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the results. Statistical significance was determined using one-way ANOVA with Dunnett’s multiple
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2.6. Effect of HpTYMS-G4-T on the Levels of TYMS mRNA and Protein
To confirm a specific decrease in TYMS gene expression, TYMS mRNA levels in cervical carcinoma
cells (HeLa) treated with HpTYMS-G4-T for 24 h or 48 h were analyzed. Cells incubated with
HpTYMS-G4-T showed a decrease in TYMS gene expression, both at 24 h and 48 h (1.6-2.1-fold decrease
relative to control) (Figure 6A). In addition, a 65% decrease in TYMS protein levels was observed after
24 h of incubation with the HpTYMS-G4-T (Figure 6B,C).
2.7. Effect of HpTYMS-G4-T as a Single Agent or Combined with 5-FU on HeLa Cell Viability
Since TYMS is involved in the de novo synthesis of dTTP, inhibition of TYMS expression using
HpTYMS-G4-T was expected to reduce the viability of cancer cells and to produce a higher effect
when the incubation was carried out in thymidine deficient medium. Therefore, HpTYMS-G4-T
was incubated either in the presence or in the absence of thymidine. The PPRH was cytotoxic in a
dose-dependent manner in both media, whereas HpSC4 did not produce any effect on cell viability.
The highest cytotoxicity was reached at 100 nM in the absence of thymidine, with less than 5% of the
viable cells remaining (Figure 7A). Once the effectiveness of HpTYMS-G4-T was established, we studied
the effects of combining this specific PPRH with 5-FU, a classic inhibitor of TYMS protein. The PPRH
(15 nM) presented a synergic effect when combined with different doses of 5-FU (0.3, 1 and 3 µM),
reducing cell viability down to 38%, 30%, and 14%, respectively (combination index calculated by the
CompusSyn software [42]) (Figure 7B).
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Figure 7. Effect on HeLa cell viability of HpTYMS-G4-T. (A) Dose–response of HeLa cell viability
upon treatment with the HpTYMS-G4 and the HpSC4 in the absence (RPMI medium) or presence of
thymidine (F12 medium). (B) Effect on cell viability when combining HpTYMS-G4-T with 5-FU. HeLa
cells were treated with 5-FU at different concentrations (0.3, 1, 3 µM) in the absence or presence of
HpTYMS-G4-T (15 nM). Statistical significance was determined using two-way ANOVA with Sidak’s
multiple comparisons test (*** p < 0.001, **** p < 0.0001). When combining the PPRH with 5-FU,
statistical significance was estimated by comparing the effect of the PPRH alone to the control or
comparing the effect of 5-FU plus PPRH to 5-FU alone. When transfecting the PPRH at 100 nM, 10 µM of
DOTAP was used, whereas for 15 nM or 30 nM of PPRH, 5 µM DOTAP was employed.
As a control, the influence of 5-FU as a single agent on TYMS expression was also addressed.
HeLa cells incubated for 24 h with 3 µM of 5-FU showed a slight increase in TYMS mRNA levels,
which were re-established after 48 h. At the protein level, a three-fold increase in total TYMS protein
was observed after 24 h (Figure S3). These results are in agreement with [43–45].
2.8. Effect of HpTYMS-G4-T on PC-3 Cell Viability and mRNA Levels
W further examined whether the a tiproliferative effect of HpTYMS-G4-T on HeLa cells was
reproducible in other human cancer cell lines. HpTYMS-G4-T also produced a decrease in the viability
of prostate adenocarcinoma cells (PC-3) in a dose–response manner, with only 4% of the viable cells
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remaining at a concentration of 100 nM of PPRH (Figure 8A). In addition, after 24 h of transfection,
PC-3 cells treated with 30 nM or 100 nM of HpTYMS-G4-T showed a 45% and 60% decrease in TYMS
mRNA levels relative to the control, respectively (Figure 8B).
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levels. After 24 h of transfection, RNA extraction was conducted and RNA levels determined by
RT-qPCR. PPIB was used to normalize the results. Statistical significance was determined using
one-way ANOVA with Dunnett’s multiple comparisons test (** p < 0.01, **** p < 0.0001).
3. Discussion
In this work, we describe the effects of a PPRH targeting a polypyrimidine strand complementary
to a newly identified G4 motif present in the 5’UTR of the TYMS gene, whose encoded protein is a
classical anti-cancer target due to its role in DNA synthesis [2]. Since it is known that G4 structures can
be important gene regulatory elements, we searched for G4 structures in the TYMS gene using the
QGRS mapper, a computational tool for the prediction of quadruplex forming G-rich sequences [12,46].
The spectroscopic experiments carried out in this work confirmed that the G4FS detected in the 5’UTR
of the TYMS gene by the QGRS apper fold into a G4 structure as both RNA and DNA.
Since there was a discrepancy in the extension of the 5’UTR sequence of the human TYMS mRNA
in the last two accession numbers (NM_001071.4 and NM_001071.3) available in the NCBI database,
we verified by PCR and RT-PCR that the G4FS identified in this work was actually located in the 5’UTR
of the TYMS gene and not in its promoter sequence, in agreement with the original sequence for the
TYMS gene reported in [32].
Interestingly, some metabolic enzymes have been described as multifunctional proteins performing
distinct biochemical functions in the cytoplasm and nucleus, which are involved in transcriptional,
posttranscriptional and translational regulation. Among them, we find glyceraldehyde 3-phosphate
dehydrogenase, arg 5,6, enoyl-CoA hydratase, lactate dehydrogenase, threonyl-tRNA-synthetase,
dihydrofolate reductase and Thymidylate synthase [47–49]. Moreover, it has been demonstrated that
G4FS are putative protein binding regions that can act as regulatory elements of gene expression [12].
For these reasons, we aimed to study whether TYMS protein could directly interact with the G4FS
present in its own 5’UTR (TYMS-G4FS). Since TYMS is a self-mRNA targeting protein binding to at least
two different sites and inhibiting its own translation [8,9], we also evaluated the possible interaction
between TYMS and the G4FS as mRNA species. This was confirmed by EMSA, thus proving that this
protein has another binding site in its own mRNA that could also correspond to a translational regulator.
In addition, we explored whether TYMS protein was also interacting with the dsDNA formed
by the TYMS-G4FS and its complementary strand, as this interaction could be important for the
regulation of gene expression at the transcriptional level. EMSAs showed the specific binding of TYMS
protein to the G4FS site, both as dsDNA and ssDNA. The same G4FS site, through its polypyrimidine
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tract, was targeted by the binding of the designed PPRH (HpTYMS-G4-T), which caused a decrease
in the expression of TYMS. These results suggest that TYMS protein could be involved in its own
transcriptional regulation upon binding to this G4FS site.
Altogether, the observed interactions between TYMS protein and G4FS, either as mRNA or DNA,
highlight that this site could be involved in translational and transcriptional regulation. Moreover,
it has been previously demonstrated that C-MYC [50], p53 [51,52] and IFN-induced 15 kDa protein [53]
mRNA translation is also controlled by TYMS, highlighting the important role of TYMS protein
regulating not only its own expression but also that of other proteins.
Furthermore, in this work, we uncover the importance of the TYMS-G4FS region in the regulation
of TYMS expression. Whether G4 structures promote or inhibit transcriptional or translational processes
is a discrepant issue. While some studies indicate that G4s may positively contribute to gene expression
through protein binding, others maintain that G4 structures may act as obstacles [54]. For instance, it has
been reported that a G4 located in the C-MYC promoter interacts with the nucleic acid binding protein
(CNBP) and NM23-H2, contributing to the enhancement of its own transcription [55]. In contrast,
Kumari et al. reported that a G4 structure located in the 5’UTR of the NRAS mRNA inhibited its
own translation [56]. This could also be the function of the G4FS identified in the 5’UTR of TYMS.
One hypothesis is that the interaction that we observed between TYMS protein and the G4FS, either as
DNA or RNA, could be preventing the function of the transcriptional or translational machineries.
According to this premise, when TYMS is bound by its substrates (mTHF and dUMP) or by TYMS
inhibitors, it does not interact with G4FS, thus increasing TYMS expression and leading to resistance
to inhibitors. This proposition is in concordance with the currently postulated TYMS autoregulatory
mechanism [8,9], but with an additional self-mRNA binding site and extrapolating the effect at the
transcriptional level.
In view of the relevant role of G4 motifs in the regulation of gene expression, a wide range of G4
ligands have been developed for anti-tumor applications, such as ligands that stabilize G4 structures
in the telomere region to block telomerase activity [57,58] and those targeting G4 structures located in
promoters, 5’UTRs or 3’UTRs to regulate different cancer-related genes [12,59–62]. Several G4 ligands
have demonstrated their potential in vivo [63] and some have reached clinical trials [64–67]. However,
one of the main problems with these compounds is their lack of specificity and the possible off-target
effects due to the high number of putative G4 structures present in the human genome [20,68].
In contrast, PPRHs can be designed to bind specifically to a polypyrimidine sequence that is
complementary to a given G4FS. In fact, we proved that HpTYMS-G4-T binds in a specific manner
to its target sequence, located in the complementary polypyrimidine strand of G4FS. Accordingly,
our binding assays with ThT staining showed that even in conditions in which a PPRH can fold into a
G4 structure, this does not impair its binding to the dsDNA, thus confirming our previous data [41].
In addition, dsDNA/PPRH triplex formation promoted the displacement of the polypurine strand
and its folding into a G4 structure, thus the PPRH may contribute to stabilizing the formation of the
G4 structure and would regulate transcription of this gene. We also corroborated the notion that
Hoogsteen bonds stabilizing the PPRH are essential for triplex formation, since the Watson–Crick
hairpin HpTYMS-G4-WC was not able to form the triplex.
One of the goals of this work was to demonstrate the effect of HpTYMS-G4-T on cancer cells. In this
regard, we demonstrated that the PPRH targeting G4FS decreased both TYMS mRNA and protein
levels in a specific manner. This down-regulation of TYMS expression led to a decrease in cell viability
in a dose-dependent manner in both HeLa and PC3 cancer cells. It is worth noting that the cytotoxic
effect of HpTYMS-G4-T was lower when cells were incubated in medium containing thymidine.
Similarly, Schmitz et al. also reported that the effect of a siRNA targeting TYMS mRNA was reversed
with 10 µM of thymidine [69]. These data suggest that the cytotoxic effect of HpTYMS-G4-T results
from the inhibition of thymidylate biosynthesis, caused by the specific inhibition of TYMS expression.
Other gene silencing molecules such as siRNAs [10,69], ASOs [70–72] or peptides [73] targeting
TYMS mRNA also succeeded in down-regulating TYMS expression. However, PPRHs present some
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advantages compared to other silencing tools. PPRHs are nonmodified DNA molecules that inhibit
gene expression at lower concentrations than those needed for ASOs [22], they are more economical,
less immunogenic and have a longer half-life than siRNAs [74]. Recently, we also demonstrated in a
pharmacogenomic study that PPRHs do not present hepatotoxicity or nephrotoxicity in vitro [75].
In addition, since TYMS’s autoregulatory translation mechanism has been associated with
traditional TYMS inhibitor resistance [6–8], we evaluated the effect of HpTYMS-G4-T in combination
with 5-FU. We demonstrated the synergic effect of HpTYMS-G4-T in HeLa cells treated concurrently
with 5-FU. Our results are in accordance with others proving that strategies focused on reducing TYMS
gene expression can sensitize cells to traditional TYMS inhibitors [69,72].
Overall, in this work, we identified and confirmed a G4 structure in the 5’UTR of the TYMS gene
that could be involved in transcriptional and translational autoregulation of TYMS expression. We also
showed that a PPRH designed against this G4FS presented therapeutic potential as a single agent or in
combination with 5-FU treatment. Therefore, we provide new insights for the design of strategies that
improve the effect of traditional TYMS inhibitors.
4. Materials and Methods
4.1. Bioinformatic Detection of G4-Forming Sequences
Putative G4FS were analyzed using the QGRS mapper (http://bioinformatics.ramapo.edu/QGRS/
index.php). This software program generates information on the composition and distribution of
putative QGRS in nucleotide sequences and is based on published algorithms for the recognition and
mapping of putative QGRS [46].
4.2. Design of Polypurine Reverse Hoogsteen Hairpins
The search of polypurine sequences that serve to design PPRH hairpins was performed using the
Triplex-Forming Oligonucleotide Target Sequence Search software (http://utw10685.utweb.utexas.edu/tfo/
MD Anderson Cancer Center, University of Texas) [33]. The design consisted of two antiparallel
mirror repeats of polypurine stretches, intramolecularly bound by reverse Hoogsteen bonds and linked
by a loop of five thymidines (5T). As negative controls, we designed a hairpin with intramolecular
Watson–Crick bonds instead of Hoogsteen bonds (HpTYMS-G4-T-WC) and a scrambled hairpin
(HpSC4) (Figure 1E). The sequences were synthetized as non-modified oligodeoxynucleotides by
Sigma-Aldrich (Haverhill, UK), resuspended in sterile Tris-EDTA buffer (1 mM EDTA and 10 mM Tris,
pH 8.0) (Sigma-Aldrich, Madrid, Spain) and stored at −20 ◦C until use.
4.3. RNA and gDNA Extraction
Total RNA was extracted from cells using TRIzol®(Life Technologies, Barcelona, Spain), following the
manufacturer’s specifications. RNA intended for PCR assays was treated with DNAse I, RNAse-free
(ThermoFisher, Barcelona, Spain). Total gDNA was extracted using the Wizard genomic DNA
purification kit (Promega, Madrid, Spain), following the manufacturer’s instructions. RNA and gDNA
concentrations were determined by measuring its absorbance at 260 nm using a NanoDrop ND-1000
spectrophotometer (ThermoFisher, Barcelona, Spain).
4.4. Reverse Transcription
cDNA was synthesized in a 20 µL reaction mixture containing 1 µg of total RNA, 125 ng of random
hexamers (Roche, Spain), 500 µM of each deoxynucleotide triphosphate (Bioline, Barcelona, Spain),
2 µL of buffer (10×), 20 units of RNAse inhibitor and 200 units of Moloney murine leukemia virus
reverse transcriptase (Last three from Lucigen, WI, USA). The reaction was carried out at 42 ◦C for 1 h.
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4.5. PCR
gDNA and cDNA samples from HeLa cells were used as templates to perform PCR reactions in
order to locate sequences corresponding to the 5’UTR. Reactions were performed in a final volume of
50 µL containing either 500 ng of gDNA or 250 ng of cDNA, 5 µL of buffer 5×, 500 ng forward primer,
500 ng reverse primer, 200 µM dNTPs (Bioline, Barcelona, Spain), 1.25 U OneTaq DNA polymerase
(New England Biolabs, Barcelona, Spain) and H2O mQ. Cycling conditions were as follows: 3 min
denaturation at 94 ◦C, followed by 30 cycles of 30 s at 94 ◦C, 1 min at 59 ◦C and 1 min at 68 ◦C,
and a final extension step of 5 min at 68 ◦C. PCR products were resolved in a nondenaturing 6%
polyacrylamide gel electrophoresis in 1× TBE buffer. Gels were visualized using Gel Doc™ EZ and the
Image Lab Software, Version 6.0 (Bio-Rad, Madrid, Spain). Forward (5’UTR-TYMS-Fw) and reverse
primers (5’UTR-TYMS-Rv) were designed to hybridize to a sequence located 32 nt upstream and 109 nt
downstream from the G4FS, respectively. The 5’UTR-TYMS-Rv primer covers 25 nt of the translating
mRNA. The 184 bp PCR product was sequenced in Macrogen (Amsterdam, the Netherlands).
We confirmed that the DNAse digestion was completely achieved by performing a PCR with
primers located in exon 1 (APRT-Ex1-Fw) and exon 2 (APRT-Ex2-Rv) of the human APRT gene,
intervened by a short intron of 163 bp. The amplification of the gDNA sample led to a product of
291 bp (including intron 1), whereas in the case of the RNA (treated with DNAse), the product had a
length of 128 bp (excluding intron 1). Primer sequences are shown in Table 1.
4.6. CD and UV Absorbance Spectroscopy
The CD spectra were recorded on a JASCO spectropolarimeter J-810 at 20 ◦C with a scanning
speed of 100 nm/min, a response time of 4 s, 0.5 nm data pitch and 1 nm bandwidth. The samples
(4 µM) were dissolved in the above buffers, annealed and slowly cooled to room temperature and left
at 4 ◦C for at least one night.
The thermal melting curves were obtained following the absorption change at 295 nm for the
ODN from 15 ◦C to 70 ◦C, with a linear temperature ramp of 0.5◦/min in Teflon-stoppered 1-cm
path-length quartz cells, on a JASCO V-650 spectrophotometer equipped with a Peltier temperature
control. UV spectra of the oligonucleotides were recorded at 15◦ (folded) and 80 ◦C (unfolded) to
calculate the TDS. The measurements were conducted in either 10 mM sodium cacodylate buffer plus
100 mM KCl (pH 7.0) or PBS.
4.7. Thioflavin T Fluorescence Spectroscopy
ThT titrations were carried out with a JASCO FP-6200 spectrofluorometer with a temperature-
controlled circulator JASCO ETC-272T. The fluorescence spectra were acquired using a quartz cuvette
with a 10-mm path length. In the fluorescence measurements, both the excitation and emission
slits were 10 nm, the excitation wavelength was set to 430 nm, and the scan speed was 250 nm/min.
Fluorescence spectra were recorded between 450 to 650 nm. ThT (3 µM) was titrated with increasing
concentrations of ODN (O-6 µM) to measure the binding constant. The fluorescence intensity at 491 nm
was plotted as a function of the oligonucleotide concentration. The data were fitted according to a 1:1
binding model.
4.8. Nuclear Magnetic Resonance
The sample for NMR was prepared by dissolving the oligonucleotide at 180 µM concentration in
25 mM K2HPO4; pH7, 100 mM KCl buffer containing 10% D2O. NMR spectra were acquired with a
Bruker QANUC 800 MHz spectrometer equipped with a cryoprobe and processed with TOPSPIN 2.1
software. An excitation sculpting pulse program was used to supress the water signal while detecting
rapid interchangeable imino protons.
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4.9. RT-qPCR
To determine TYMS mRNA levels, a QuantStudio 3 Real-Time PCR System (Applied Biosystems,
Barcelona, Spain) was used. The reaction was performed in a final volume of 20 µL, containing 1×
SYBR Universal PCR Master mix (Applied Biosystems, Barcelona, Spain), 0.25 µM of reverse and
forward primers (Sigma- Aldrich, Madrid, Spain), 3 µL of cDNA and H2O mQ. PCR cycling conditions
were 10 min denaturation at 95 ◦C, followed by 40 cycles of 15 s at 95 ◦C and 1 min at 60 ◦C. The mRNA
quantification was performed using the ∆∆Ct method, where Ct is the threshold cycle that corresponds
to the cycle where the amount of amplified mRNA reaches the threshold of fluorescence. Cyclophylin
B (PPIB) was used as an endogenous control to normalize the results. Primer sequences for RT-qPCR
are detailed in Table 1.
4.10. Electrophoretic Mobility Shift Assay
To perform EMSA analyses, the dsDNA probe corresponding to G4FS was obtained by mixing equal
amounts of each single-stranded oligodeoxynucleotide in a 150 mM NaCl solution. After incubation at
90 ◦C for 5 min, the solution was allowed to cool down slowly to room temperature. The duplex was
resolved in a nondenaturing 20% polyacrylamide gel, visualized using UV shadowing and purified
from the gel. DNA concentration was measured as stated in Section 4.3 of Materials and Methods.
dsDNA, ssDNA and RNA probes (200 ng) were 5’-end-labeled with (γ-32P)-ATP (3000 Ci/mmol)
(Perkin Elmer, Madrid, Spain) using T4 polynucleotide kinase (New England BioLabs, MA, USA)
in a 10 µL reaction mixture, according to the manufacturer’s instructions. After incubation at 37 ◦C
for 1 h, 90 µL of Tris-EDTA buffer (1 mM EDTA and 10 mM Tris, pH 8.0; Sigma-Aldrich, Madrid,
Spain) was added to the reaction mixture, which was subsequently filtered through a Sephadex G-25
(Sigma-Aldrich, Madrid, Spain) spin-column to eliminate the unincorporated (γ-32P)-ATP.
Radio-labeled probes (100,000 cpm, [γ-32P]-ATP) were incubated with either HeLa nuclear protein
extracts, purified TYMS or HpTYMS-G4-T PPRH. Both BSA and DHFR proteins were used as negative
controls. Poly(dI:dC) (3 µg) was added to each reaction as an unspecific competitor. Binding reactions
were performed in the presence of a binding buffer (5% glycerol, 0.5 mM DTT, 4 mM MgCl2, 36 mM KCl,
0.5 mM EDTA, 25 mM Tris-HCl, pH 8.0; all reagents were purchased from Sigma-Aldrich). The products
of the binding reactions were electrophoretically resolved in 5% polyacrylamide and 5% glycerol
native gels in 0.5× TBE buffer, at a fixed voltage of 220 V and 4 ◦C. Gels were dried at 80 ◦C and
scanned on a Storm 840 PhosphorImager (Molecular Dynamics, GE Healthcare Life Sciences, Barcelona,
Spain). ImageQuant software v5.2 was used to visualize and quantify the results (GE Healthcare,
Barcelona, Spain).
4.11. Detection of G4 Structures with ThT upon DNA Binding Assays
To detect G4 structures after DNA binding assays, 1.5 µg of each oligonucleotide, alone or
combined with the indicated oligonucleotide, was incubated at 90 ◦C for 5 min in water, then diluted
with a buffer containing 100 mM KCl and 100 mM Tris/HCl (pH 7.5) in a final volume of 100 µL and
slowly cooled to room temperature (2 h).
Samples (75 µL) were loaded on nondenaturing 12% polyacrylamide gels (10 cm) containing
10 mM KCl in 1× TBE buffer and electrophoresed for 1–2 h at 150 V. After electrophoresis, gels were
stained with 5 µM of ThT solution for 15 min under agitation, briefly washed in water, and exposed to
a UV light lamp to obtain images. Then, the same gels were further stained with 1 µg/mL ethidium
bromide solution for 10 min under agitation and washed for 10 min in water. Images were captured
under a UV light lamp or using the Gel DocTM EZ with the Image Lab Software, Version 6.0.
4.12. Cell Culture
HeLa and PC-3 cell lines obtained from the cell bank resources from University of Barcelona
were grown in Ham’s F12 medium supplemented with 10% fetal bovine serum (GIBCO, Invitrogen,
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Barcelona, Spain) or in Roswell Park Memorial Institute medium (RPMI), which is deficient in
thymidine, supplemented with 7% dialyzed fetal bovine serum and incubated at 37 ◦C in a humidified
5% CO2 atmosphere.
4.13. Transfection of the PPRH
One day before transfection, cells were plated in 6-well dishes in 800 µL of either
F12 or RPMI medium. The transfection consisted of mixing N-[1-(1,2-Di-(9Z-octadecenoyl)-3-
trimethylammoniumpropane methyl sulfate (DOTAP; Biontex, Germany) with the PPRH and
serum-free medium in volumes of up to 200µL. Unless stated otherwise, the molar ratio of PPRH/DOTAP
was 1:100 (100 nM/10 µM). After 20 min of incubation at room temperature, the mixture was added to
the cells to attain a final volume of 1 mL.
4.14. Western Blot Analyses
Total protein extracts from HeLa cells (30,000) were obtained using 100µL of RIPA buffer (1% Igepal,
0.5% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 10 mM NaF and 50 mM
Tris-HCl, pH 8, containing additionally the Protease inhibitor cocktail (P8340-5ML); all the above were
purchased from Sigma Aldrich, Madrid, Spain, but Tris-HCl was from PanReac AppliChem, Barcelona,
Spain). Extracts were incubated for 5 min at 4 ◦C and cell debris was removed by centrifugation
(16,300× g at 4 ◦C for 10 min). Protein concentrations were determined using a Bio-Rad protein assay
based on the Bradford method and using bovine serum albumin as a standard.
Protein extracts were electrophoresed in 10% SDS-polyacrylamide gels and transferred to
polyvinylidene difluoride membranes. Blocking of membranes was performed using 5% Blotto.
In the case of primary antibody against TYMS (1:100 dilution; sc-376161, Santa Cruz Biotechnology,
Heidelberg, Germany), membranes were probed overnight at 4 ◦C, whereas primary antibody
against α-Tubulin (1:100 dilution; CP06, Merck, Darmstadt, Germany) membranes were probed
for 90 min at room temperature. Signals of both proteins were detected by secondary horseradish
peroxidase-conjugated anti-mouse antibody (1:2500 dilution; sc-516102, Santa Cruz Biotechnology,
Heidelberg, Germany). Chemiluminescence was detected with the ImageQuant LAS 4000 mini imager
(GE Healthcare, Barcelona, Spain). Quantification was performed using the ImageQuant 5.2 software.
4.15. Combination Treatment of 5-FU plus HpTYMS-G4-T
Cells were plated in 6-well dishes in RPMI medium one day before transfection or 5-FU treatment.
The 5-FU (Sigma-Aldrich, Madrid, Spain) was prepared from powder as a 100 mM stock solution in
DMSO and diluted in RPMI medium. The transfection was performed as indicated in the Section 4.13,
Transfection. Cells were incubated with 5-FU alone or combined concurrently with the PPRH in a final
volume of 1 mL.
4.16. MTT Assay
Cells (10,000) were plated in 6-well dishes in F12 medium or RPMI medium. Five days after
transfection or 5-FU treatment, 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and
sodium succinate (both from Sigma-Aldrich, Madrid, Spain) were added to the culture medium
(final concentration 0.63 mM and 100 µM, respectively) and incubated for 2.5 h at 37 ◦C. Then,
the culture medium was removed and the lysis solution (0.57% of acetic acid and 10% of SDS in
DMSO) (Sigma-Aldrich, Madrid, Spain) was added. Absorbance was measured at 570 nm in a
Modulus Microplate spectrophotometer (Turner BioSystems, Madrid, Spain). Cell viability results
were expressed as the percentage of cell survival relative to the controls.
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4.17. Statistical Analyses
Statistical analyses were performed using GraphPad Prism 6 (GraphPad Software, CA, USA).
All data are shown as the mean± SEM of at least three independent experiments. The levels of statistical
significance were denoted as follows: p < 0.05 (*), p < 0.01 (**), p < 0.001 (***) or p < 0.0001 (****).
5. Conclusions
In this work, we identified a G4FS in the 5’UTR of the TYMS gene and confirmed its folding into
a G4 structure in both DNA and RNA backbones. Additionally, we determined that TYMS protein
directly interacts with G4FS either as dsDNA, ssDNA or RNA, which may be involved in transcriptional
and translational autoregulation of TYMS expression. Finally, the HpTYMS-G4-T PPRH targeting the
complementary strand of the G4FS decreased both TYMS mRNA and protein levels in cancer cells,
leading to cell death and showing a synergic effect in combination with 5-FU.
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References
1. Carreras, C.W.; Santi, D.V. The Catalytic Mechanism and Structure of Thymidylate Synthase. Annu. Rev. Biochem.
1995, 64, 721–762. [CrossRef] [PubMed]
2. Rose, M.G.; Farrell, M.P.; Schmitz, J.C. Thymidylate synthase: A critical target for cancer chemotherapy.
Clin. Colorectal Cancer 2002, 1, 220–229. [CrossRef] [PubMed]
3. Gmeiner, W. Novel Chemical Strategies for Thymidylate Synthase Inhibition. Curr. Med. Chem. 2012,
12, 191–202. [CrossRef] [PubMed]
4. Longley, D.B.; Harkin, D.P.; Johnston, P.G. 5-Fluorouracil: Mechanisms of action and clinical strategies.
Nat. Rev. Cancer. 2003, 3, 330–338. [CrossRef] [PubMed]
5. Zhang, N.; Yin, Y.; Xu, S.J.; Chen, W.S. 5-Fluorouracil: Mechanisms of resistance and reversal strategies.
Molecules 2008, 13, 1551–1569. [CrossRef]
6. Berger, S.H.; Jenh, C.H.; Johnson, L.F.; Berger, F.G. Thymidylate synthase overproduction and gene
amplification in fluorodeoxyuridine-resistant human cells. Mol. Pharmacol. 1985, 28, 461–467.
Int. J. Mol. Sci. 2020, 21, 5028 18 of 21
7. Rooney, P.H.; Stevenson, D.A.J.; Marsh, S.; Johnston, P.G.; Haites, N.E.; Cassidy, J.; McLeod, H.L.
Comparative genomic hybridization analysis of chromosomal alterations induced by the development of
resistance to thymidylate synthase inhibitors. Cancer Res. 1998, 58, 5042–5045.
8. Chu, E.; Koeller, D.M.; Casey, J.L.; Drake, J.C.; Chabner, B.A.; Elwood, P.C.; Zinn, S.; Allegra, C.J.
Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase.
Proc. Natl. Acad. Sci. USA 1991, 88, 8977–8981. [CrossRef]
9. Chu, E.; Voeller, D.; Koeller, D.M.; Drake, J.C.; Takimoto, C.H.; Maley, G.F.; Maley, F.; Allegra, C.J. Identification
of an RNA binding site for human thymidylate synthase. Proc. Natl. Acad. Sci. USA 1993, 90, 517–521.
[CrossRef]
10. Garg, D.; Henrich, S.; Salo-Ahen, O.M.H.; Myllykallio, H.; Costi, M.P.; Wade, R.C. Novel approaches for
targeting thymidylate synthase to overcome the resistance and toxicity of anticancer drugs. J. Med. Chem.
2010, 53, 6539–6549. [CrossRef]
11. Brunn, N.D.; Dibrov, S.M.; Kao, M.B.; Ghassemian, M.; Hermann, T. Analysis of mRNA recognition by
human thymidylate synthase. Biosci. Rep. 2014, 34, 905–913. [CrossRef]
12. Tian, T.; Chen, Y.Q.; Wang, S.R.; Zhou, X. G-Quadruplex: A Regulator of Gene Expression and Its Chemical
Targeting. Chem 2018, 4, 1314–1344. [CrossRef]
13. Gellert, M.; Lipsett, M.N.; Davies, D.R. Helix formation by guanylic acid. Proc. Natl. Acad. Sci. USA 1962,
48, 2013–2018. [CrossRef] [PubMed]
14. Davis, J.T. G-Quartets 40 Years Later: From 5′-GMP to Molecular Biology and Supramolecular Chemistry.
Angew. Chem. Int. Ed. 2004, 43, 668–698. [CrossRef] [PubMed]
15. Lane, A.N.; Chaires, J.B.; Gray, R.D.; Trent, J.O. Stability and kinetics of G-quadruplex structures.
Nucleic Acids Res. 2008, 36, 5482–5515. [CrossRef]
16. Hänsel-Hertsch, R.; di Antonio, M.; Balasubramanian, S. DNA G-quadruplexes in the human genome:
Detection, functions and therapeutic potential. Nat. Rev. Mol. Cell Biol. 2017, 18, 279–284. [CrossRef]
17. Rhodes, D.; Lipps, H.J. Survey and summary G-quadruplexes and their regulatory roles in biology.
Nucleic Acids Res. 2015, 43, 8627–8637. [CrossRef]
18. Bugaut, A.; Balasubramanian, S. 5′-UTR RNA G-quadruplexes: Translation regulation and targeting.
Nucleic Acids Res. 2012, 40, 4727–4741. [CrossRef]
19. Song, J.; Perreault, J.-P.; Topisirovic, I.; Richard, S. RNA G-quadruplexes and their potential regulatory roles
in translation. Translation 2016, 4, e1244031. [CrossRef]
20. Chambers, V.S.; Marsico, G.; Boutell, J.M.; di Antonio, M.; Smith, G.P.; Balasubramanian, S. High-throughput
sequencing of DNA G-quadruplex structures in the human genome. Nat. Biotechnol. 2015, 33, 877–881.
[CrossRef]
21. Ciudad, C.J.; Rodríguez, L.; Villalobos, X.; Félix, A.J.; Noé, V. Polypurine Reverse Hoogsteen Hairpins as a
Gene Silencing Tool for Cancer. Curr. Med. Chem. 2017, 24, 2809–2826. [CrossRef] [PubMed]
22. De Almagro, M.C.; Coma, S.; Noé, V.; Ciudad, C.J. Polypurine hairpins directed against the template strand
of DNA knock down the expression of mammalian genes. J. Biol. Chem. 2009, 284, 11579–11589. [CrossRef]
[PubMed]
23. Goñi, J.R.; de la Cruz, X.; Orozco, M. Triplex-forming oligonucleotide target sequences in the human genome.
Nucleic Acids Res. 2004, 32, 354–360. [CrossRef]
24. Rodríguez, L.; Villalobos, X.; Dakhel, S.; Padilla, L.; Hervas, R.; Hernández, J.L.; Ciudad, C.J.; Noé, V.
Polypurine reverse Hoogsteen hairpins as a gene therapy tool against survivin in human prostate cancer
PC3 cells in vitro and in vivo. Biochem. Pharmacol. 2013, 86, 1541–1554. [CrossRef]
25. De Almagro, M.C.; Mencia, N.; Noé, V.; Ciudad, C.J. Coding polypurine hairpins cause target-induced cell
death in breast cancer cells. Hum. Gene Ther. 2011, 22, 451–463. [CrossRef]
26. Villalobos, X.; Rodríguez, L.; Solé, A.; Lliberós, C.; Mencia, N.; Ciudad, C.J.; Noé, V. Effect of polypurine
reverse hoogsteen hairpins on relevant cancer target genes in different human cell lines. Nucleic Acid Ther.
2015, 25, 198–208. [CrossRef]
27. Aubets, E.; Noé, V.; Ciudad, C.J. Targeting replication stress response using polypurine reverse hoogsteen
hairpins directed against WEE1 and CHK1 genes in human cancer cells. Biochem. Pharmacol. 2020, 175, 113911.
[CrossRef] [PubMed]
Int. J. Mol. Sci. 2020, 21, 5028 19 of 21
28. Bener, G.; Félix, A.J.; de Diego, C.S.; Fabregat, I.P.; Ciudad, C.J.; Noé, V. Silencing of CD47 and SIRPα by
Polypurine reverse Hoogsteen hairpins to promote MCF-7 breast cancer cells death by PMA-differentiated
THP-1 cells. BMC Immunol. 2016, 17, 32. [CrossRef]
29. Ciudad, C.J.; Enriquez, M.M.M.; Félix, A.J.; Bener, G.; Noé, V. Silencing PD-1 and PD-L1: The potential of
PolyPurine Reverse Hoogsteen hairpins for the elimination of tumor cells. Immunotherapy 2019, 11, 369–372.
[CrossRef]
30. Enríquez, M.M.M.; Félix, A.J.; Ciudad, C.J.; Noé, V. Cancer immunotherapy using PolyPurine Reverse
Hoogsteen hairpins targeting the PD-1/PD-L1 pathway in human tumor cells. PLoS ONE. 2018, 13, e0206818.
31. Mencia, N.; Selga, E.; Noé, V.; Ciudad, C.J. Underexpression of miR-224 in methotrexate resistant human
colon cancer cells. Biochem. Pharm. 2011, 82, 1572–1582. [CrossRef] [PubMed]
32. Kaneda, S.; Nalbantoglu, J.; Takeishi, K.; Shimizu, K.; Gotoh, O.; Seno, T.; Ayusawa, D. Structural and
functional analysis of the human thymidylate synthase gene. J. Biol. Chem. 1990, 265, 20277–20284.
33. Gaddis, S.S.; Wu, Q.; Thames, H.D.; Digiovanni, J.; Walborg, E.F.; Macleod, M.C.; Vasquez, K.M. A web-based
search engine for triplex-forming oligonucleotide target sequences. Oligonucleotides 2006, 16, 196–201.
[CrossRef]
34. Mergny, J.-L.; Phan, A.-T.; Lacroix, L. Following G-quartet formation by UV-spectroscopy. FEBS Lett. 1998,
435, 74–78. [CrossRef]
35. Paramasivan, S.; Rujan, I.; Bolton, P.H. Circular dichroism of quadruplex DNAs: Applications to structure,
cation effects and ligand binding. Methods 2007, 43, 324–331. [CrossRef] [PubMed]
36. Mergny, J.-L.; Li, J.; Lacroix, L.; Amrane, S.; Chaires, J.B. Thermal difference spectra: A specific signature for
nucleic acid structures. Nucleic Acids Res. 2005, 33, e138. [CrossRef] [PubMed]
37. Kettani, A.; Kumar, R.A.; Patel, D.J. Solution structure of a DNA quadruplex containing the fragile X
syndrome triplet repeat. J. Mol. Biol. 1995, 254, 638–656. [CrossRef]
38. Mohanty, J.; Barooah, N.; Dhamodharan, V.; Harikrishna, S.; Pradeepkumar, P.I.; Bhasikuttan, A.C. Thioflavin
T as an Efficient Inducer and Selective Fluorescent Sensor for the Human Telomeric G-Quadruplex DNA.
J. Am. Chem. Soc. 2013, 135, 367–376. [CrossRef] [PubMed]
39. Maiti, S.; Chaudhury, N.K.; Chowdhury, S. Hoechst 33258 binds to G-quadruplex in the promoter region of
human c-myc. Biochem. Biophys. Res. Commun. 2003, 310, 505–512. [CrossRef]
40. De la Faverie, A.R.; Guédin, A.; Bedrat, A.; Yatsunyk, L.A.; Mergny, J.L. Thioflavin T as a fluorescence
light-up probe for G4 formation. Nucleic Acids Res. 2014, 42, e65. [CrossRef]
41. Solé, A.; Delagoutte, E.; Ciudad, C.J.; Noé, V.; Alberti, P. Polypurine reverse-Hoogsteen (PPRH)
oligonucleotides can form triplexes with their target sequences even under conditions where they fold into
G-quadruplexes. Sci. Rep. 2017, 7, 1–11. [CrossRef]
42. Chou, T.-C. Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method.
Cancer Res. 2010, 70, 440–446. [CrossRef] [PubMed]
43. Ligabue, A.; Marverti, G.; Liebl, U.; Myllykallio, H. Transcriptional Activation and Cell Cycle Block Are the
Keys for 5-Fluorouracil Induced Up-Regulation of Human Thymidylate Synthase Expression. PLoS ONE
2012, 7, e47318. [CrossRef] [PubMed]
44. Peters, G.J.; Backus, H.H.J.; Freemantle, S.; van Triest, B.; Codacci-Pisanelli, G.; van der Wilt, C.L.; Smid, K.;
Lunec, J.; Calvert, A.H.; Marsh, S.; et al. Induction of thymidylate synthase as a 5-fluorouracil resistance
mechanism. Biochim. Biophys. Acta Mol. Basis Dis. 2002, 1587, 194–205. [CrossRef]
45. Peters, G.J.; van Triest, B.; Backus, H.H.J.; Kuiper, C.M.; van der Wilt, C.L.; Pinedo, H.M. Molecular
downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell
lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed. Eur. J. Cancer
2000, 36, 916–924. [CrossRef]
46. Kikin, O.; D’Antonio, L.; Bagga, P.S. QGRS Mapper: A web-based server for predicting G-quadruplexes in
nucleotide sequences. Nucleic Acids Res. 2006, 34, W676–W682. [CrossRef]
47. Chu, E.; Takimoto, C.H.; Voeller, D.; Grem, J.L.; Allegra, C.J. Specific Binding of Human Dihydrofolate
Reductase Protein to Dihydrofolate Reductase Messenger RNA in Vitro. Biochemistry 1993, 32, 4756–4760.
[CrossRef]
48. Bhardwaj, A.; Wilkinson, M.F. A metabolic enzyme doing double duty as a transcription factor. BioEssays
2005, 27, 467–471. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 5028 20 of 21
49. Zheng, L.; Roeder, R.G.; Luo, Y. S Phase Activation of the Histone H2B Promoter by OCA-S, a Coactivator
Complex that Contains GAPDH as a Key Component. Cell 2003, 114, 255–266. [CrossRef]
50. Chu, E.; Takechi, T.; Jones, K.L.; Voeller, D.M.; Copur, S.M.; Maley, G.F.; Maley, F.; Segal, S.; Allegra, C.J.
Thymidylate synthase binds to c-myc RNA in human colon cancer cells and in vitro. Mol. Cell. Biol. 1995,
15, 179–185. [CrossRef]
51. Ju, J.; Pedersen-Lane, J.; Maley, F.; Chu, E. Regulation of p53 expression by thymidylate synthase. Proc. Natl.
Acad. Sci. USA 1999, 96, 3769–3774. [CrossRef] [PubMed]
52. Chu, E.; Copur, S.M.; Ju, J.; Chen, T.; Khleif, S.; Voeller, D.M.; Mizunuma, N.; Patel, M.; Maley, G.F.;
Maley, F.; et al. Thymidylate Synthase Protein and p53 mRNA Form an In Vivo Ribonucleoprotein Complex.
Mol. Cell. Biol. 1999, 19, 1582–1594. [CrossRef]
53. Chu, E. Identification of in vivo target RNA sequences bound by thymidylate synthase. Nucleic Acids Res.
1996, 24, 3222–3228. [CrossRef]
54. Cogoi, S.; Shchekotikhin, A.E.; Xodo, L.E. HRAS is silenced by two neighboring G-quadruplexes and
activated by MAZ, a zinc-finger transcription factor with DNA unfolding property. Nucleic Acids Res. 2014,
42, 8379–8388. [CrossRef] [PubMed]
55. Chen, S.; Su, L.; Qiu, J.; Xiao, N.; Lin, J.; Tan, J.H.; Ou, T.M.; Gu, L.Q.; Huang, Z.S.; Li, D. Mechanistic studies for
the role of cellular nucleic-acid-binding protein (CNBP) in regulation of c-myc transcription. Biochim. Biophys.
Acta Gen. Subj. 2013, 1830, 4769–4777. [CrossRef] [PubMed]
56. Kumari, S.; Bugaut, A.; Huppert, J.L.; Balasubramanian, S. An RNA G-quadruplex in the 5′ UTR of the
NRAS proto-oncogene modulates translation. Nat. Chem. Biol. 2007, 3, 218–221. [CrossRef]
57. Kim, M.Y.; Vankayalapati, H.; Shin-Ya, K.; Wierzba, K.; Hurley, L.H. Telomestatin, a potent telomerase
inhibitor that interacts quite specifically with the human telomeric intramolecular G-quadruplex. J. Am.
Chem. Soc. 2002, 124, 2098–2099. [CrossRef]
58. Zahler, A.M.; Williamson, J.R.; Cech, T.R.; Prescott, D.M. Inhibition of telomerase by G-quartet DMA
structures. Nature 1991, 350, 718–720. [CrossRef]
59. Asamitsu, S.; Obata, S.; Yu, Z.; Bando, T.; Sugiyama, H. Recent progress of targeted G-quadruplex-preferred
ligands toward cancer therapy. Molecules 2019, 24, 429. [CrossRef]
60. Siddiqui-Jain, A.; Grand, C.L.; Bearss, D.J.; Hurley, L.H. Direct evidence for a G-quadruplex in a promoter
region and its targeting with a small molecule to repress c-MYC transcription. Proc. Natl. Acad. Sci. USA
2002, 99, 11593–11598. [CrossRef]
61. Wang, S.K.; Wu, Y.; Wang, X.Q.; Kuang, G.T.; Zhang, Q.; Lin, S.L.; Liu, H.Y.; Tan, J.H.; Huang, Z.S.; Ou, T.M.
Discovery of Small Molecules for Repressing Cap-Independent Translation of Human Vascular Endothelial
Growth Factor (hVEGF) as Novel Antitumor Agents. J. Med. Chem. 2017, 60, 5306–5319. [CrossRef]
62. Beaudoin, J.D.; Perreault, J.P. Exploring mRNA 3′-UTR G-quadruplexes: Evidence of roles in both alternative
polyadenylation and mRNA shortening. Nucleic Acids Res. 2013, 41, 5898–5911. [CrossRef] [PubMed]
63. Che, T.; Wang, Y.Q.; Huang, Z.L.; Tan, J.H.; Huang, Z.S.; Chen, S.B. Natural alkaloids and heterocycles as
G-quadruplex ligands and potential anticancer agents. Molecules 2018, 23, 493.
64. Xu, H.; di Antonio, M.; McKinney, S.; Mathew, V.; Ho, B.; O’Neil, N.J.; Santos, N.D.; Silvester, J.; Wei, V.;
Garcia, J.; et al. CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient
tumours. Nat. Commun. 2017, 8, 14432. [CrossRef]
65. Khot, A.; Brajanovski, N.; Cameron, D.P.; Hein, N.; Maclachlan, K.H.; Sanij, E.; Lim, J.; Soong, J.; Link, E.;
Blombery, P.; et al. First-in-human RNA polymerase I transcription inhibitor CX-5461 in patients with
advanced hematologic cancers: Results of a phase I dose-escalation study. Cancer Discov. 2019, 9, 1036–1049.
[CrossRef]
66. Drygin, D.; Siddiqui-Jain, A.; O’Brien, S.; Schwaebe, M.; Lin, A.; Bliesath, J.; Ho, C.B.; Proffitt, C.; Trent, K.;
Whitten, J.P.; et al. Anticancer activity of CX-3543: A direct inhibitor of rRNA biogenesis. Cancer Res. 2009,
69, 7653–7661. [CrossRef] [PubMed]
67. Local, A.; Zhang, H.; Benbatoul, K.D.; Folger, P.; Sheng, X.; Tsai, C.Y.; Howell, S.B.; Rice, W.G. APTO-253
stabilizes G-quadruplex DNA, inhibits MYC expression, and induces DNA damage in acute myeloid
leukemia cells. Mol. Cancer Ther. 2018, 17, 1177–1186. [CrossRef] [PubMed]
68. Huppert, J.L.; Balasubramanian, S. Prevalence of quadruplexes in the human genome. Nucleic Acids Res.
2005, 33, 2908–2916. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 5028 21 of 21
69. Schmitz, J.C.; Chen, T.M.; Chu, E. Small Interfering Double-Stranded RNAs as Therapeutic Molecules to
Restore Chemosensitivity to Thymidylate Synthase Inhibitor Compounds. Cancer Res. 2004, 64, 1431–1435.
[CrossRef]
70. Jason, T.L.H.; Berg, R.W.; Vincent, M.D.; Koropatnick, J. Antisense targeting of Thymidylate Synthase
(TS) mRNA increases TS gene transcription and TS protein: Effects on human tumor cell sensitivity to TS
enzyme-inhibiting drugs. Gene Expr. 2007, 13, 227–239. [CrossRef]
71. Ferguson, P.J.; Collins, O.; Dean, N.M.; DeMoor, J.; Sha-Li, C.; Vincent, M.D.; Koropatnick, J.
Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of
5-FUdR, 5-FU and Tomudex in HeLa cells. Br. J. Pharmacol. 1999, 127, 1777–1786. [CrossRef] [PubMed]
72. Berg, R.W.; Ferguson, P.J.; Vincent, M.D.; Koropatnick, D.J. A “combination oligonucleotide” antisense
strategy to downregulate thymidylate synthase and decrease tumor cell growth and drug resistance.
Cancer Gene Ther. 2003, 10, 278–286. [CrossRef] [PubMed]
73. Yan, S.; Niu, R.L.; Wang, Z.; Lin, X.K. In vitro selected peptides bind with thymidylate synthase mRNA and
inhibit its translation. Sci. China Ser. C Life Sci. 2007, 50, 630–636. [CrossRef]
74. Villalobos, X.; Rodríguez, L.; Prévot, J.; Oleaga, C.; Ciudad, C.J.; Noé, V. Stability and immunogenicity
properties of the gene-silencing polypurine reverse hoogsteen hairpins. Mol. Pharm. 2014, 11, 254–264.
[CrossRef]
75. Félix, A.J.; Ciudad, C.J.; Noé, V. Functional pharmacogenomics and toxicity of PolyPurine Reverse Hoogsteen
hairpins directed against survivin in human cells. Biochem. Pharmacol. 2018, 155, 8–20. [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
